Age: 19 Years – 65 YearsPhase: NAReported sites: 1Sponsor: University of South Alabama
The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg…
Age: 40 Years and olderPhase: PHASE2Reported sites: 1Sponsor: Yale University
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Age: 40 Years and olderPhase: PHASE2Reported sites: 1Sponsor: Yale University
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Age: 40 Years and olderPhase: PHASE2Reported sites: 1Sponsor: Joshua Woolley, MD, PhD
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Age: 30 Days and olderPhase: Not ApplicableReported sites: 1Sponsor: New York Stem Cell Foundation Research Institute
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.
Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Age: 40 Years and olderPhase: PHASE2Reported sites: 1Sponsor: VA Office of Research and Development
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target…